Elezanumab + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Cord Injury (SCI)
Conditions
Spinal Cord Injury (SCI)
Trial Timeline
Sep 6, 2020 → Jan 26, 2026
NCT ID
NCT04295538About Elezanumab + Placebo
Elezanumab + Placebo is a phase 2 stage product being developed by AbbVie for Spinal Cord Injury (SCI). The current trial status is completed. This product is registered under clinical trial identifier NCT04295538. Target conditions include Spinal Cord Injury (SCI).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04309474 | Phase 2 | Completed |
| NCT04295538 | Phase 2 | Completed |
| NCT03737812 | Phase 2 | Completed |
| NCT03737851 | Phase 2 | Completed |
Competing Products
20 competing products in Spinal Cord Injury (SCI)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUN13837 injection + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg | Astellas Pharma | Phase 2 | 52 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 2 | 52 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 1 | 33 |
| Elezanumab | AbbVie | Pre-clinical | 23 |
| Ropivacaine + Bupivacaine | AstraZeneca | Phase 3 | 77 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 1 | 33 |
| Zolgensma | Novartis | Pre-clinical | 23 |
| BVS857 + Placebo | Novartis | Phase 2 | 52 |
| AVXS-101 | Novartis | Phase 1 | 33 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 77 |
| Onasemnogene Abeparvovec-brve | Novartis | Approved | 85 |
| Onasemnogene Abeparvovec-xioi | Novartis | Pre-clinical | 23 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 77 |
| branaplam | Novartis | Phase 1/2 | 41 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 77 |
| onasemnogene abeparvovec | Novartis | Phase 3 | 77 |
| onasemnogene abeparvovec-xioi | Novartis | Phase 3 | 77 |
| Risdiplam | Roche | Phase 1 | 33 |
| ATI355 | Novartis | Phase 1 | 33 |